353 results
To compare the pharmacokinetics, pharmacodynamics, safety and tolerability of a subcutaneous formulation with an intravenous formulation of ARGX-113 in healthy male subjects
This study has been transitioned to CTIS with ID 2024-513538-40-02 check the CTIS register for the current data. To determine the value of quantitative whole body PET with [18F]PEG-Folate to predict development of clinical arthritis within one year…
The goals of this study is to identify and validate recently discovered and novel biomarkers of pathophysiology, diagnosis, classification, disease activity, prognosis, treatment susceptibility, and treatment efficacy in IMIDs.
Primary Objective: Test the capacity of drug candidates to specifically inhibit the signalling pathways they target in human blood cells in vitro in the setting of human whole blood.Secondary Objective(s): Test whether drug candidates exert…
The main objective of the current study is to determine factors that are markers for disease activity, future progression and may be indicative for specific organ involvement. In the current project we will focus on the following objectives: I)…
To study patients with clinically suspect arthralgia in order to 1) develop diagnostic/prognostic markers (a. markers of systemic and b. local inflammation as well as c. autoantibodies) for the development of RA 2) to improve the mechanistic…
to combine and validate diagnostic tests for the prediction of clinical response to therapy with biologics in patients withreumatoid artritis.
Primary objectives are:To assess the diagnostic accuracy of DWI in the evaluation of disease activity in JIA as compared to contrast-enhanced MRI as the reference standard.To assess the accuracy of DWI in detecting joint inflammation as compared to…
ObjectivePlease describe:• the specific goal to be reached by the study• the hypothesis to be answered by the studyThe overall aim of the study is to determine which downstream cellular and molecular pathways involved in PsA pathogenesis are…
Primary objective: to assess gender differences in the risk of flaring after the tapering of TNF inhibition.Secondary objectives: 1. to assess gender differences in body composition in AS patients with sustained low disease activity during TNF-…
The purpose of this study is to investigate how quickly and to what extent evobrutinib is absorbed, distributed, metabolized (broken down) and eliminated from the body (this is called pharmacokinetics). Part of the evobrutinib will be labelled with…
The main objective of this trial is to investigate safety of long term use of inhaled molgramostim by collecting information on the side effects.
The purpose of this study is to investigate the influence of the new compound BMS986165 on the absorption, distribution, and elimination (this is called pharmacokinetics) of methotrexate (MTX) from the body, when it is administered to healthy…
The main objective is to describe in detail the variation in clinical subtypes, clinical course, past and current practice of treatment, antibody titers, and clinical picture of IgM monoclonal gammopathy associated polyneuropathy at the various…
The primary objective of this study is to investigate if shear-wave elastography and contrast-enhanced ultrasonography can identify those patients most suitable fir an intervention (surgery or endoscopic balloon dilation) and those patients that…
The proportion of patients in GC-free remission after 20 weeks.
Primary objectiveTo evaluate the safety and tolerability of a single intra-articular administration of ART-I02, a recombinant adeno-associated virus (AAV) type 2/5 vector expressing human IFN-β in patients with RA or OA and active arthritis of the…
Primary Objective: Development of a tracer kinetic model for tracers [11C]DPA-713 and [18F]PEG-Folate.Secondary Objectives: 1. Development of a static imaging protocol and a validated simplified measure for quantification of uptake of tracers [11C]…
The purpose of the study is to investigate how quickly and to what extent PF 04965842 is absorbed, distributed, metabolized (broken down) and eliminated from the body (this is called pharmacokinetics). A small part of the PF 04965842 to be…
The primary objective is to identify molecular signatures that can serve as diagnostic and/or severity-of-disease markers for PsA and markers that can predict treatment response in patients with PsA. The secondary objective is to elucidate the…